Best response to blinatumomab, follow-up treatment, and relapse for individual long-term survivors
| Patient No.* . | Cohort . | Best response† . | MRD response . | Allo-SCT after blinatumomab . | RFS duration (mo) . | Blinatumomab retreatment after relapse . | OS duration (mo) . |
|---|---|---|---|---|---|---|---|
| 5 | 2b | CR | Yes | No | 17.5 | Yes | 38.6 |
| 8 | 3 | CR | Yes | Yes | 34.5‡ | No | 35.0 |
| 10 | 3 | CRh | Yes | No | 22.4‡ | No | 30.0§ |
| 20 | 2b | CR | Yes | No | 34.1‡ | No | 36.9 |
| 23 | 3 | Hypocellular | Yes | Yes | N/A | No | 29.7§ |
| 26 | 3 | CR | Yes | Yes | 11.5 | No | 31.9‖ |
| 27 | 3 | CR | Yes | Yes | 23.5‡ | No | 30.3 |
| 29 | 2a | CR | Yes | No¶ | 2.8 | No | 41.9 |
| 31 | 3 | CRh | Yes | Yes | 27.9‡ | No | 30.2 |
| 32 | 3 | CR | Yes | Yes | 29.9‡ | No | 30.3 |
| Patient No.* . | Cohort . | Best response† . | MRD response . | Allo-SCT after blinatumomab . | RFS duration (mo) . | Blinatumomab retreatment after relapse . | OS duration (mo) . |
|---|---|---|---|---|---|---|---|
| 5 | 2b | CR | Yes | No | 17.5 | Yes | 38.6 |
| 8 | 3 | CR | Yes | Yes | 34.5‡ | No | 35.0 |
| 10 | 3 | CRh | Yes | No | 22.4‡ | No | 30.0§ |
| 20 | 2b | CR | Yes | No | 34.1‡ | No | 36.9 |
| 23 | 3 | Hypocellular | Yes | Yes | N/A | No | 29.7§ |
| 26 | 3 | CR | Yes | Yes | 11.5 | No | 31.9‖ |
| 27 | 3 | CR | Yes | Yes | 23.5‡ | No | 30.3 |
| 29 | 2a | CR | Yes | No¶ | 2.8 | No | 41.9 |
| 31 | 3 | CRh | Yes | Yes | 27.9‡ | No | 30.2 |
| 32 | 3 | CR | Yes | Yes | 29.9‡ | No | 30.3 |
N/A, not applicable.
Patient No. refers to patients listed in supplemental Table 1.
Best response during the treatment period.
Patient was still relapse-free at the time of the analysis.
Patient had an OS of ≥30 mo after rounding to the nearest whole value.
Death.
Chemotherapy was administered after blinatumomab and before allo-SCT.